Twist Bioscience (TWST) Cash & Equivalents (2018 - 2026)

Twist Bioscience (TWST) has reported Cash & Equivalents for 9 consecutive years, with $122.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 41.68% year-over-year to $122.7 million; the TTM figure through Mar 2026 stood at $122.7 million (down 41.68% YoY), while the FY2025 annual figure was $183.0 million, down 19.12% from the prior year.
• Cash & Equivalents retreated to $122.7 million in Q1 2026 per TWST's latest filing, from $148.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $407.6 million in Q1 2022 and bottomed at $122.7 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $261.8 million across 5 years, with a median of $243.3 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 65.26% — and 2026, when it tumbled 41.68%.
• Twist Bioscience's Cash & Equivalents stood at $316.7 million in 2022, then declined by 15.92% to $266.3 million in 2023, then dropped by 16.85% to $221.4 million in 2024, then plunged by 32.89% to $148.6 million in 2025, then declined by 17.42% to $122.7 million in 2026.
• Business Quant data shows TWST's Cash & Equivalents at $122.7 million in Q1 2026, $148.6 million in Q4 2025, and $183.0 million in Q3 2025.